Alvotech and Teva Pharmaceuticals on Friday announced that they have signed a new long-term agreement with an undisclosed strategic partner in order to make its Humira biosimilar Simlandi (adalimumab-ryvk) more accessible to U.S. patients.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,